CEVR Leaders Publish NEJM Article on Determining Value Using Cost-Effectiveness Analyses
Peter Neumann, Sc.D., Joshua Cohen, Ph.D., and Daniel Ollendorf, Ph.D. of the Center for the Evaluation of Value and Risk [...]
Biden Picks Califf As Safe Bet for FDA Commissioner
Biden has nominated Robert Califf to lead the Food and Drug Administration (FDA). Although Califf’s position at Google’s Verily has [...]
Upcoming December Webinar on RWE in Pharma Featuring Leaders at IQVIA, Roche, and Janssen
The Evidence Base will host a webinar on real world evidence (RWE) in pharma at 7:00 AM on December 8th, [...]
Pelosi’s Politicking Leads to Drug Pricing Deal
After 15 years, Democrats have managed to advance drug pricing legislation. House Speaker Nancy Pelosi unexpectedly opposed Medicare negotiation in [...]
PBMs Collect Millions in Missing Ohioan Medicaid Funds Amid Clawback Questions
According to Ohio Medicaid Director Maureen Corcoran at a legislative watchdog hearing, pharmacy benefit managers (PBMs) have collected millions of [...]
Democrats’ Pricing Legislation Insufficient; PhRMA’s Criticism of Policies Unwarranted
Attempts to reduce drug costs via policy changes are insufficient. Despite the relatively small scale of new legislation, including allowing [...]
PhRMA Proposes Multi-Pronged Solutions to Drug Affordability Crisis
The Pharmaceutical Research and Manufacturers of America (PhRMA) discussed several solutions that would reduce healthcare costs for patients while maintaining [...]
Two New PBMs Promise Patient Centricity and Pricing Transparency
EmsanaRx and Mark Cuban’s Cost Plus startup are the latest pharmacy benefit management (PBM) companies promising transparency and a patient-centered [...]
[Whitepaper] Can Streamlining Rebates Bring Financial Success?
Model N is offering a whitepaper that highlights cost-saving improvements for manufacturers of medical technology. “This white paper will help [...]
Podcast on Clinical Trial Challenges and FDA Solutions
A recent episode of the Business of Biotech podcast series features Allan Shaw. This installment highlights some of the major problems arising [...]
[World Congress] eBook on Assessing Risk for Pharma Manufacturer Programs
A new eBook, sponsored by TrialCard, details risk mitigation strategies for pharma. Many co-pay assistance programs are facing a wide [...]
Robert Califf’s Ties to Big Tech Bring Scrutiny
Could Robert Califf lead the Food and Drug Administration (FDA)? Not until he explains his ties to technology companies. It’s [...]
xCures Seeks to Improve Patient Outcomes Using Targeted Oncology RWD
xCures aims to improve the outcomes of patients with cancer using real world data (RWD) tools. Quickly identifying relevant patient [...]
Newly Launched Bespoke Gene Therapy Consortium Raises $76 Million to Advance Rare Disease Research
The Food and Drug Administration, the National Institutes of Health, and the Foundation for the Institutes of Health have announced [...]
Biden Administration Rethinks Medicare Negotiation
Democratic attempts to curb drug prices have been hindered by conflict within the party as well as external lobbying by [...]
Pharma Gears Up for Pricing Battle as Democrats Scale Back Legislation
Democrats are gradually reducing the scope of legislation intended to reduce drug prices. The pharmaceutical industry has voiced its opposition [...]
Panalgo VP Discusses Changes to ICER’s Value Assessments Ahead of Mid-November Webinar
HealthEconomics.Com Founder and CEO Dr. Patti Peeples recently spoke with Panalgo’s Matt Sussman regarding changes to the value assessments carried [...]
Parexel VPs Discuss COVID-19, RWE, and New Challenges
Parexel’s Leanne Larson and Matthew Gordon shared their thoughts on the growing importance of real world evidence (RWE) in clinical [...]
Biogen Reports Low Aduhelm Sales Amid Medicare Uncertainty
Biogen reported low sales of Alzheimer’s drug Aduhelm. Although the Centers for Medicare and Medicaid (CMS) are unable to negotiate [...]
Value in Health Editors Issue Call for Papers on Drug Costs
The editors of Value in Health have issued a call for papers related to prescription drug costs throughout the product [...]
PRMA Consulting’s eBook on Market Access in Asia-Pacific Now Available
PRMA Consulting is offering an eBook on market access in the Asia-Pacific (APAC) region. Unlike European systems that primarily revolve [...]
Genesis Research Improves EVID AI Tool to Streamline Literature Reviews and Advance RWE
Genesis Research has revealed updates to its EVID AI resource. The improvements will help researchers to quickly identify relevant articles [...]
Comprehensive Literature Review on HTA Applications of Regulatory Sandboxes Now Available
A recent article, published in Applied Health Economics and Health Policy, describes how the regulatory sandbox could impact Health Technology [...]
PRMA Consulting Leader Discusses Strategies to Address Healthcare Inequities
PRMA Consulting’s Alisha Robert discusses how organizations can address healthcare inequities. Key strategies include using social determinants of health combined [...]
New Ideagen Whitepaper on Data Integrity in the Life Sciences
Ideagen has published a whitepaper on maintaining data integrity in your life sciences organization. The paper includes important insights on [...]